Dr. Thomas J. Gergel
Claim this profileGuthrie Medical Group PC-Robert Packer Hospital
Studies Lung Cancer
Studies Breast Cancer
6 reported clinical trials
20 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage II
Stage I
2Breast Cancer
HER2 positive
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Thomas J. Gergel is currently running
Radiation Therapy + Olaparib
for Breast Cancer
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
Recruiting1 award Phase 248 criteria
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
More about Thomas J. Gergel
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Thomas J. Gergel has experience with
- Docetaxel
- Gemcitabine
- Erlotinib Hydrochloride
- Local Consolidation Therapy
- Pemetrexed Disodium
- Single Fraction Stereotactic Radiosurgery
Breakdown of trials Thomas J. Gergel has run
Lung Cancer
Breast Cancer
Small Cell Lung Cancer
Small Cell Carcinoma
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas J. Gergel specialize in?
Thomas J. Gergel focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Thomas J. Gergel currently recruiting for clinical trials?
Yes, Thomas J. Gergel is currently recruiting for 2 clinical trials in Sayre Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Thomas J. Gergel has studied deeply?
Yes, Thomas J. Gergel has studied treatments such as Docetaxel, Gemcitabine, Erlotinib Hydrochloride.
What is the best way to schedule an appointment with Thomas J. Gergel?
Apply for one of the trials that Thomas J. Gergel is conducting.
What is the office address of Thomas J. Gergel?
The office of Thomas J. Gergel is located at: Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania 18840 United States. This is the address for their practice at the Guthrie Medical Group PC-Robert Packer Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.